Active • Host: E. coli • AA: Met1; 32-101 • MW: 7.8 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PF4/CXCL4 (human, recombinant)

Item No. 44199

Technical Information
Synonyms
  • Endothelial Cell Growth Inhibitor
  • Iroplact
  • C-X-C Motif Chemokine 4
  • Oncostatin-A
  • Platelet Factor 4
Purity
≥80% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU/g, determined by the LAL endotoxin assay
Source
Active recombinant human PF4/CXCL4 expressed in E. coli
Amino Acids
Met1; 32-101
MW
7.8 kDa
Lyophilized from sterile PBS, pH 7.4, with 5% trehalose, 5% mannitol, and 0.01% Tween 80
Host
E. coli
UniProt Accession №
P02776
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Platelet factor 4 (PF4), also known as chemokine (C-X-C) motif ligand 4 (CXCL4), is a chemokine produced by activated platelets with roles in coagulation, innate and adaptive immunity, and aging.1,2,3 It is produced as a 70-amino acid monomer, but functions as both a monomer and higher order oligomers in vivo.4 PF4 binds to heparin to inhibit its anticoagulation activity, and it facilitates platelet aggregation and interacts with chemokine (C-X-C) motif receptor 1 (CXCR1) and CXCR2 on polymorphonuclear leukocytes (PMNs) at sites of tissue injury to induce intramuscular accumulation and wound healing.5 It is released in response to microorganisms to induce neutrophil recruitment and in response to viral infection to stimulate antigen presenting cells and induce both pro- and antiviral effects.1 Plasma levels of PF4 are positively correlated with the progression of lung and skin fibrosis and pulmonary arterial hypertension.2 Decreased serum levels of PF4 are associated with cognitive decline in patients with Alzheimer’s disease.3 Cayman’s PF4/CXCL4 (human, recombinant) protein can be used for cell-based assay and Western blot (WB) applications. The protein was synthesized from a DNA sequence encoding the mature form of PF4 (Glu32-Ser101) with an N-terminal translation-initiating methionine (Met1). The expressed protein consists of 71 amino acids, has a calculated molecular weight of 7.8 kDa, and a predicted N-terminus of Met1.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cai, Z., Greene, M.I., Zhu, Z., et alStructural features and PF4 functions that occur in heparin-induced thrombocytopenia (HIT) complicated by COVID-19. Antibodies (Basel) 9(4), 52 (2020).

    2. Liu, Z., Li, L., Zhang, H., et alPlatelet factor 4(PF4) and its multiple roles in diseases. Blood Rev. 64, 101155 (2026).

    3. Li, L., and Xie, C. PF4 in rejuvenation therapy: Neuroprotection and cognitive enhancement. Biomol. Biomed. 25(11), 2580-2584 (2025).

    4. Zhang, X., Chen, L., Bancroft, D.P., et alCrystal structure of recombinant human platelet factor 4. Biochemistry 33(27), 8361-8366 (1994).

    5. Weyrich, A.S., and Zimmerman, G.A. Platelets: Signaling cells in the immune continuum. Trends Immunol. 25(9), 489-495 (2004).